Executive Summary Hunter Brook Capital's investigative report uncovers how CVS Health, UnitedHealth Group, and Cigna Group engineered secretive PBM group purchasing organization (GPO) subsidiaries; Zinc, Emisar, and Ascent; to divert billions in drug rebates away from health plans and patients. Despite claims of "100% rebate pass-through,"

Two Natural Capital examines the competitive landscape of RNA therapeutics targeting muscular diseases, revealing significant technical hurdles and potentially inflated claims from companies attempting to replicate Alnylam's RNAi success beyond the liver. While Alnylam has expanded from one liver-targeted drug in 2018 to six approvals today, competitors pursuing

Ticker: VRL (Vedanta Resources Limited) Position Disclosure: Viceroy Research may hold positions in related securities Report Type: Critical Analysis / Short Research Original Source: Viceroy Research Report THESIS The key findings include: * Tax Evasion Structure: India's Income Tax Department (ITD) alleges Vedanta Holdings Mauritius 2 Limited (VHM2L), which holds